Alnylam Pharmaceuticals, Inc. (ALNY) P/E Ratio History
UndervaluedTrading at 66.9x vs 5Y avg 443.6x · 40th percentile · Below historical baseline · Data 2025–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) trades at a price-to-earnings ratio of 66.9x, with a stock price of $155.94 and trailing twelve-month earnings per share of $19.74.
The current P/E is 85% below its 5-year average of 443.6x. Over the past five years, ALNY's P/E has ranged from a low of 12.5x to a high of 1900.0x, placing the current valuation at the 40th percentile of its historical range.
Compared to the Healthcare sector median P/E of 25.1x, ALNY trades at a 167% premium to its sector peers. The sector includes 229 companies with P/E ratios ranging from 0.0x to 195.0x.
Relative to the broader market, ALNY commands a significant premium over the S&P 500 median P/E of 26.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ALNY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ALNY Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ALNY P/E vs Peers
RNA Medicines peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $93B | 21.8Lowest | 3.44Best | +8%Best | |
| $37B | 28.1 | - | -21% | |
| $11B | 31.1 | - | -19% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ALNY Historical P/E Data (2025–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $246.74 | $19.80 | 12.5x | -97% |
| FY2026 Q2 | - | $301.03 | $5.92 | 50.8x | -89% |
| FY2026 Q1 | - | $330.87 | $4.21 | 78.6x | -82% |
| FY2025 Q4 | Dec 31 2025 | $397.65 | $2.26 | 176.0x | -60% |
| FY2025 Q3 | - | $456.00 | $0.24 | 1900.0x | +328% |
Average P/E for displayed period: 443.6x
ALNY Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ALNY — Frequently Asked Questions
Quick answers to the most common questions about buying ALNY stock.
What is ALNY's P/E ratio?
Alnylam Pharmaceuticals, Inc. (ALNY) trailing twelve-month P/E ratio is 66.9x, based on TTM diluted EPS of $19.74. The 5-year average P/E is 443.6x and the historical range spans 12.5x to 1900.0x.
Is ALNY stock overvalued or undervalued?
ALNY trades at 66.9x P/E, below its 5-year average of 443.6x. At the 40th percentile of its historical range (12.5x–1900.0x), the stock is priced at a discount to its own history.
Is ALNY stock expensive?
No, ALNY is not expensive on a historical basis. The current P/E of 66.9x is below the 5-year average of 443.6x and sits at the 40th percentile of its valuation range.
What is ALNY's historical P/E range?
Over the past 5 years, ALNY's P/E ratio has ranged from 12.5x to 1900.0x, with a median of 78.6x and an average of 443.6x. The current P/E of 66.9x places the stock at the 40th percentile of this range. Full historical data spans 2025–2026.
How does ALNY's P/E compare to the S&P 500?
ALNY trades at 66.9x P/E versus the S&P 500 median of 26.3x. The 154% premium to the market typically reflects higher expected earnings growth or quality.
How does ALNY's valuation compare to Healthcare peers?
Alnylam Pharmaceuticals, Inc. P/E of 66.9x compares to the Healthcare sector median of 25.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ALNY's PEG ratio?
ALNY PEG ratio is N/A, based on a P/E of 66.9x and EPS growth of 206.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ALNY's earnings yield?
ALNY earnings yield is 1.49%, the inverse of its 66.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.